Solana’s Mango Markets DEX Raises $70M in MNGO Token Sale

Solana’s Mango Markets DEX Raises $70M in MNGO Token Sale

The team behind Mango Markets – a decentralized exchange on the high-speed Solana blockchain – raised $70 million in a token sale Wednesday.

At its height, investors had plowed over $500 million in USDC during the cross-margin trading platform’s 24-hour sale, racing to get a share of 500 million MNGO tokens up for grabs. But much of that drained away in the final minutes of a daylong grace period that followed, leaving $70,462,383 locked up in tokens.

The raise from a still-nascent project reflects the rising fortunes of the Solana blockchain – and a hope by token-sale investors that Mango’s MNGO can be for Solana what Uniswap’s UNI is for Ethereum. Many decentralized finance (DeFi) protocols aim to raise between $1 million and $15 million in seed stage funding, one source said.

The sale was closed to U.S. persons, likely in an attempt to stave off the regulatory scrutiny that can hamstring similar projects – sometimes years down the line.

The DAO’s website said MNGO has three purposes: to capitalize an insurance fund; to distribute the DEX governance token; and to incentivize liquidity for market makers. Ninety percent of tokens are locked up in a governance fund, 5% in an insurance policy and the remainder in contributor tokens.

The entirety of Wednesday’s raise will go to DAO’s insurance fund, securing a hefty backstop for Mango Protocol’s lenders if things go south, sources familiar with the raise told CoinDesk. Exploits happen in the wild west of decentralization, and Mango DAO cautioned token buyers that they could not guarantee its smart contracts would be bug-free. (The sale took place against the backdrop of Tuesday’s $600 million heist on Poly Network.)

Solana Labs, the leading firm behind the network, raised $314 million in June. Solana itself has been the blockchain of choice for FTX founder Sam Bankman-Fried, who has invested heavily in Solana-based projects including fellow DEX Serum.

Source

Subscribe to get our top stories